Claims for Patent: 6,488,960
✉ Email this page to a colleague
Summary for Patent: 6,488,960
Title: | Corticosteroid formulation |
Abstract: | The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration. |
Inventor(s): | Bardsley; Hazel Judith (Cambridge, GB) |
Assignee: | Arakis Ltd. (GB) |
Application Number: | 09/936,586 |
Patent Claims: |
1. A controlled-release formulation comprising from 0.25 mg to 2 mg of a corticosteroid selected from the group consisting of prednisone, methylprednisolone, and prednisolone,
wherein said formulation is adapted to release at least 90% by weight of the corticosteroid 2 hours to 8 hours after administration.
2. The formulation according to claim 1, which comprises from 0.5 mg to 2 mg of the corticosteroid. 3. The formulation according to claim 1, which comprises from 1 mg to 1.25 mg of the corticosteroid. 4. The formulation according to claim 1, wherein the corticosteroid is prednisolone. 5. A method for the treatment of rheumatoid arthritis, wherein said method comprises administering to a patient an effective amount of a controlled-release formulation comprising from 0.25 mg to 2 mg of a corticosteroid selected from the group consisting of prednisone, methylprednisolone, and prednisolone, wherein said formulation is adapted to release at least 90% by weight of the corticosteroid 2 hours to 8 hours after administration. 6. The method according to claim 5, wherein the formulation comprises from 0.5 mg to 2 mg of the corticosteroid. 7. The method according to claim 5, wherein the formulation comprises from 1 mg to 1.25 mg of the corticosteroid. 8. The method according to claim 5, wherein the corticosteroid is prednisolone. |